HYBIO(SZ:300199)2022-12-06 23:38Group 1: Main Products and Sales Performance - The main products of the company include Thymopentin injection, Somatostatin injection, Desmopressin acetate injection, and Terlipressin injection, which are the primary sources of revenue [2] - In 2015, the company achieved a total revenue of 768.26 million CNY, representing an increase of 83.17% year-on-year, with the formulation business contributing 410.59 million CNY, up by 25.66% [2] - In Q1 2016, Somatostatin injection revenue reached 29.60 million CNY, a growth of 80.47% compared to the same period last year, while Terlipressin injection revenue was 32.48 million CNY, increasing by 62.62% [3] Group 2: New Product Development and Market Strategy - The company is actively promoting new products such as Eptifibatide and Carboprost, with Eptifibatide receiving drug registration approval in January 2015 and GMP certification in July 2015 [3] - The company is focusing on academic promotion and market expansion for Eptifibatide, which is a third-generation antiplatelet drug recommended for coronary artery disease treatment [3] - The company is also adapting its sales strategies in response to national medical cost control policies to maintain sales volume of existing products [4] Group 3: Overseas Market Performance - In the previous year, the company reported overseas revenue of 139 million CNY, a year-on-year increase of 49.85%, with raw materials contributing 53 million CNY, up by 90.51% [4] - In Q1 2016, raw material revenue reached 48 million CNY, a staggering increase of 5,783.80% compared to the same period last year, primarily driven by the sales of Glatiramer and Liraglutide [4] - The company is experiencing strong demand for its raw materials in overseas markets due to high technical barriers and the preference of foreign pharmaceutical manufacturers for its mature technology [4]